AVDL
Price
$14.62
Change
-$0.25 (-1.68%)
Updated
Aug 28 closing price
Capitalization
1.42B
68 days until earnings call
EBS
Price
$8.39
Change
-$0.20 (-2.33%)
Updated
Aug 28 closing price
Capitalization
447.62M
68 days until earnings call
Interact to see
Advertisement

AVDL vs EBS

Header iconAVDL vs EBS Comparison
Open Charts AVDL vs EBSBanner chart's image
Avadel Pharmaceuticals
Price$14.62
Change-$0.25 (-1.68%)
Volume$1.03M
Capitalization1.42B
Emergent Biosolutions
Price$8.39
Change-$0.20 (-2.33%)
Volume$1.23M
Capitalization447.62M
AVDL vs EBS Comparison Chart in %
Loading...
AVDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVDL vs. EBS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a StrongBuy and EBS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (AVDL: $14.62 vs. EBS: $8.39)
Brand notoriety: AVDL: Notable vs. EBS: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVDL: 87% vs. EBS: 88%
Market capitalization -- AVDL: $1.42B vs. EBS: $447.62M
AVDL [@Pharmaceuticals: Generic] is valued at $1.42B. EBS’s [@Pharmaceuticals: Generic] market capitalization is $447.62M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 0 FA rating(s) are green whileEBS’s FA Score has 0 green FA rating(s).

  • AVDL’s FA Score: 0 green, 5 red.
  • EBS’s FA Score: 0 green, 5 red.
According to our system of comparison, both AVDL and EBS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 5 TA indicator(s) are bullish while EBS’s TA Score has 5 bullish TA indicator(s).

  • AVDL’s TA Score: 5 bullish, 4 bearish.
  • EBS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, AVDL is a better buy in the short-term than EBS.

Price Growth

AVDL (@Pharmaceuticals: Generic) experienced а -1.35% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -9.98% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.15%. For the same industry, the average monthly price growth was +68.06%, and the average quarterly price growth was +81.85%.

Reported Earning Dates

AVDL is expected to report earnings on Nov 05, 2025.

EBS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVDL($1.42B) has a higher market cap than EBS($448M). AVDL YTD gains are higher at: 39.106 vs. EBS (-12.238). EBS has higher annual earnings (EBITDA): 344M vs. AVDL (7.87M). EBS has more cash in the bank: 267M vs. AVDL (81.5M). AVDL has less debt than EBS: AVDL (2.73M) vs EBS (668M). EBS has higher revenues than AVDL: EBS (812M) vs AVDL (221M).
AVDLEBSAVDL / EBS
Capitalization1.42B448M317%
EBITDA7.87M344M2%
Gain YTD39.106-12.238-320%
P/E RatioN/A3.20-
Revenue221M812M27%
Total Cash81.5M267M31%
Total Debt2.73M668M0%
FUNDAMENTALS RATINGS
AVDL vs EBS: Fundamental Ratings
AVDL
EBS
OUTLOOK RATING
1..100
2718
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3741
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (53) in the Biotechnology industry is in the same range as AVDL (81) in the Medical Specialties industry. This means that EBS’s stock grew similarly to AVDL’s over the last 12 months.

AVDL's Profit vs Risk Rating (65) in the Medical Specialties industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that AVDL’s stock grew somewhat faster than EBS’s over the last 12 months.

AVDL's SMR Rating (100) in the Medical Specialties industry is in the same range as EBS (100) in the Biotechnology industry. This means that AVDL’s stock grew similarly to EBS’s over the last 12 months.

AVDL's Price Growth Rating (37) in the Medical Specialties industry is in the same range as EBS (41) in the Biotechnology industry. This means that AVDL’s stock grew similarly to EBS’s over the last 12 months.

AVDL's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as EBS (100) in the Biotechnology industry. This means that AVDL’s stock grew similarly to EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLEBS
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 24 days ago
82%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AVDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDCVX17.610.08
+0.46%
Janus Henderson International Div C
GCEPX9.94N/A
N/A
Goldman Sachs Clean Energy Income P
NBMBX18.78N/A
N/A
Neuberger Berman Mid Cap Growth Adv
TGADX30.79N/A
N/A
Templeton Growth Adv
PMCKX25.34N/A
N/A
Victory Pioneer Mid Cap Value R6

AVDL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVDL has been loosely correlated with RMTI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AVDL jumps, then RMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
-1.68%
RMTI - AVDL
34%
Loosely correlated
+22.45%
ELAN - AVDL
29%
Poorly correlated
-0.22%
HROW - AVDL
28%
Poorly correlated
+0.52%
HLN - AVDL
27%
Poorly correlated
-0.21%
EBS - AVDL
27%
Poorly correlated
-2.33%
More

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-2.33%
SIGA - EBS
47%
Loosely correlated
-0.48%
VTRS - EBS
39%
Loosely correlated
-0.10%
ELAN - EBS
35%
Loosely correlated
-0.22%
PAHC - EBS
33%
Poorly correlated
+19.44%
ZOMDF - EBS
29%
Poorly correlated
+0.24%
More